Logo image of TLRY

TILRAY BRANDS INC (TLRY) Stock Fundamental Analysis

USA - NASDAQ:TLRY - US88688T1007 - Common Stock

1.72 USD
-0.38 (-18.1%)
Last: 10/10/2025, 8:01:38 PM
1.6712 USD
-0.05 (-2.84%)
After Hours: 10/10/2025, 8:01:38 PM
Fundamental Rating

2

TLRY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. TLRY may be in some trouble as it scores bad on both profitability and health. TLRY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TLRY has reported negative net income.
In the past year TLRY has reported a negative cash flow from operations.
TLRY had negative earnings in each of the past 5 years.
TLRY had negative operating cash flow in 4 of the past 5 years.
TLRY Yearly Net Income VS EBIT VS OCF VS FCFTLRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500M -1B -1.5B -2B

1.2 Ratios

TLRY has a Return On Assets of -105.42%. This is in the lower half of the industry: TLRY underperforms 77.55% of its industry peers.
TLRY has a worse Return On Equity (-144.68%) than 67.35% of its industry peers.
Industry RankSector Rank
ROA -105.42%
ROE -144.68%
ROIC N/A
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
TLRY Yearly ROA, ROE, ROICTLRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300

1.3 Margins

The Gross Margin of TLRY (29.29%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of TLRY has grown nicely.
The Profit Margin and Operating Margin are not available for TLRY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.37%
GM growth 5YN/A
TLRY Yearly Profit, Operating, Gross MarginsTLRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLRY has been increased compared to 1 year ago.
TLRY has more shares outstanding than it did 5 years ago.
TLRY has a worse debt/assets ratio than last year.
TLRY Yearly Shares OutstandingTLRY Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
TLRY Yearly Total Debt VS Total AssetsTLRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

TLRY has an Altman-Z score of -0.33. This is a bad value and indicates that TLRY is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.33, TLRY is in line with its industry, outperforming 47.96% of the companies in the same industry.
TLRY has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
TLRY has a Debt to Equity ratio (0.19) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z -0.33
ROIC/WACCN/A
WACC7.76%
TLRY Yearly LT Debt VS Equity VS FCFTLRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

TLRY has a Current Ratio of 2.46. This indicates that TLRY is financially healthy and has no problem in meeting its short term obligations.
TLRY's Current ratio of 2.46 is in line compared to the rest of the industry. TLRY outperforms 45.41% of its industry peers.
A Quick Ratio of 1.49 indicates that TLRY should not have too much problems paying its short term obligations.
TLRY has a Quick ratio of 1.49. This is in the lower half of the industry: TLRY underperforms 61.22% of its industry peers.
Industry RankSector Rank
Current Ratio 2.46
Quick Ratio 1.49
TLRY Yearly Current Assets VS Current LiabilitesTLRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

TLRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -648.00%.
Looking at the last year, TLRY shows a small growth in Revenue. The Revenue has grown by 4.10% in the last year.
The Revenue has been growing by 37.52% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-648%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)4.1%
Revenue growth 3Y9.33%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%

3.2 Future

Based on estimates for the next years, TLRY will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.55% on average per year.
The Revenue is expected to grow by 4.43% on average over the next years.
EPS Next Y92.83%
EPS Next 2Y39.35%
EPS Next 3Y26.96%
EPS Next 5Y15.55%
Revenue Next Year3.05%
Revenue Next 2Y3.9%
Revenue Next 3Y4.1%
Revenue Next 5Y4.43%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TLRY Yearly Revenue VS EstimatesTLRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TLRY Yearly EPS VS EstimatesTLRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TLRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TLRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLRY Price Earnings VS Forward Price EarningsTLRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TLRY indicates a somewhat cheap valuation: TLRY is cheaper than 77.04% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 90.92
TLRY Per share dataTLRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

TLRY's earnings are expected to grow with 26.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.35%
EPS Next 3Y26.96%

More info and screens

0

5. Dividend

5.1 Amount

TLRY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TILRAY BRANDS INC

NASDAQ:TLRY (10/10/2025, 8:01:38 PM)

After market: 1.6712 -0.05 (-2.84%)

1.72

-0.38 (-18.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-09 2025-10-09/bmo
Earnings (Next)01-08 2026-01-08/bmo
Inst Owners9.86%
Inst Owner Change0%
Ins Owners0.36%
Ins Owner Change3.78%
Market Cap1.91B
Analysts72.5
Price Target1.03 (-40.12%)
Short Float %13.93%
Short Ratio2.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2749.13%
Min EPS beat(2)-5362.97%
Max EPS beat(2)-135.29%
EPS beat(4)0
Avg EPS beat(4)-1413.07%
Min EPS beat(4)-5362.97%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-730.51%
EPS beat(12)1
Avg EPS beat(12)-762.79%
EPS beat(16)3
Avg EPS beat(16)-613.4%
Revenue beat(2)0
Avg Revenue beat(2)-10.25%
Min Revenue beat(2)-13.28%
Max Revenue beat(2)-7.23%
Revenue beat(4)0
Avg Revenue beat(4)-8.93%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)-4.66%
Revenue beat(8)0
Avg Revenue beat(8)-5.77%
Revenue beat(12)1
Avg Revenue beat(12)-3.94%
Revenue beat(16)1
Avg Revenue beat(16)-4.24%
PT rev (1m)5.79%
PT rev (3m)-22.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)59.09%
EPS NY rev (1m)1.82%
EPS NY rev (3m)31.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.98%
Revenue NY rev (1m)-0.73%
Revenue NY rev (3m)-4.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.32
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 2.59
EV/EBITDA 90.92
EPS(TTM)-1.5
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.74
BVpS1.36
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.42%
ROE -144.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.29%
FCFM N/A
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.37%
GM growth 5YN/A
F-Score4
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA 11.15
Cap/Depr 24.66%
Cap/Sales 4.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.46
Quick Ratio 1.49
Altman-Z -0.33
F-Score4
WACC7.76%
ROIC/WACCN/A
Cap/Depr(3y)21.23%
Cap/Depr(5y)65.02%
Cap/Sales(3y)3.68%
Cap/Sales(5y)7.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-648%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y92.83%
EPS Next 2Y39.35%
EPS Next 3Y26.96%
EPS Next 5Y15.55%
Revenue 1Y (TTM)4.1%
Revenue growth 3Y9.33%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
Revenue Next Year3.05%
Revenue Next 2Y3.9%
Revenue Next 3Y4.1%
Revenue Next 5Y4.43%
EBIT growth 1Y-11.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.7%
EBIT Next 3Y29.62%
EBIT Next 5Y17.51%
FCF growth 1Y-111.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-206.1%
OCF growth 3YN/A
OCF growth 5YN/A